CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases

Completed

• Conditions: Surgical Retinal
• Interventions: Other: immunohistochemistry on Formalin fixed and paraffin embedded blocks

• Registration Number: NCT03940664
• Lead Sponsor: CHU de Reims

Brief Summary

The aims of this study were

* to analyze CD160 expression in both normal and pathological eyes from human adults

* to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease

Detailed Description

Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged over the past decade as the first line of treatment in some neovascular diseases of the retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological effect after prolonged use and.

CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic.

Study Timeline

• Study Start: 2008-01
• Primary Completion: 2017-01
• Study Completion: 2017-07
• Status Verified: 2019-05
• Study First Submitted: 2019-05-06
• Study First Submitted QC: 2019-05-06
• Last Update Submitted: 2019-05-06
• Study First Posted: 2019-05-07
• Last Update Posted: 2019-05-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
neovascular group	immunohistochemistry on Formalin fixed and paraffin embedded blocks	patients with diabetic retinopathy, retinal vein occlusion complicated with iris rubeosis or neovascular glaucoma, ocular ischaemic syndrome, neovascular glaucoma secondary to any ocular event or iris rubeosis secondary to retinal detachment
non-neovascular group	immunohistochemistry on Formalin fixed and paraffin embedded blocks	patients without neovascular diseases or complications but who underwent events leading to eye surgery such as trauma, endophthalmitis, cellulitis, anterior perforation, corneal abscess or retinal detachment.

Primary Outcome Measures

Name	Time	Method
CD160 staining intensity score	Day0	Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD160.; The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD160 immunolabelling.

Secondary Outcome Measures

Name	Time	Method
CD105 staining intensity score	Day0	Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD105.; The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD105 immunolabelling.

Trial Locations

Locations (1)

Chu Reims; 🇫🇷 France, Reims, France